The high-dose flu vaccine appeared to be more effective at preventing post-influenza deaths among older adults than the standard-dose vaccine, at least during a more severe flu season, according to a large new study of Medicare beneficiaries published in The Journal of Infectious Diseases. The findings build on earlier research suggesting that the high-dose vaccine may be better at preventing influenza virus infections and other flu-related outcomes in seniors, including office visits and hospitalizations, compared to the standard-dose vaccine.
Older adults are at high risk for serious complications from flu because of their age. In recent years, between 71 percent and 85 percent of flu-related deaths have occurred among people 65 years of age and older, according to estimates from the Centers for Disease Control and Prevention (CDC). The high-dose flu vaccine was approved in 2009 in the U.S. for adults 65 and older. "This is the population that everybody worries about," said study author David K. Shay, MD, MPH, of CDC's Influenza Division. "Many of the most serious outcomes of flu infections occur in older people."
In the study, researchers from CDC, the Centers for Medicare & Medicaid Services, and the Food and Drug Administration drew on data from Medicare beneficiaries aged 65 or older who received either the high-dose or standard-dose flu vaccine during the 2012-2013 and 2013-2014 flu seasons from community-located pharmacies. More than a million recipients of each vaccine type were studied in each of the two seasons.
During the 2012-2013 season, people who got a high-dose vaccine were 36 percent less likely to die in the 30 days following hospitalization or an emergency department visit that included a flu diagnosis compared to the standard-dose vaccine, the researchers found. H3N2 influenza viruses, which are usually associated with higher mortality in older adults, were predominant during that season. During the following season (2013-2014), when H1N1 viruses dominated and the standard-dose vaccine had better effectiveness than the previous season, the high-dose vaccine was not significantly better at preventing deaths among the Medicare patients studied.
"The high dose vaccine does appear, at least in this particular H3N2 season, to be more effective at preventing deaths that occur within 30 days of an influenza hospitalization," Dr. Shay said. "We didn't see a significant effect on post-influenza deaths during the 2013-2014 H1N1 season."
In a related editorial commentary, Arnold S. Monto, MD, of the University of Michigan School of Public Health, who was not involved in the study, noted that the findings fit well with previous data showing the high-dose flu vaccine is more effective against uncomplicated flu illness and likely hospitalizations. "This indicates that improvement in our 70-year-old influenza vaccines is possible, and to get there more quickly we should not ignore older technologies while working on more dramatic advances," Dr. Monto wrote.
- Older adults are at high risk for serious complications from flu and account for a majority of flu-related deaths and hospitalizations. H3N2 influenza viruses typically hit this age group particularly hard and have been associated with higher mortality than infections by H1N1 or influenza B viruses.
- During the 2012-2013 season, when H3N2 viruses were dominant, the high-dose flu vaccine was 36 percent more effective at preventing deaths in the Medicare beneficiaries studied, compared to the standard-dose vaccine.
- When H1N1 viruses circulated during the 2013-2014 season, the high-dose vaccine was not significantly better than the standard-dose vaccine at preventing deaths.
Editor's Note: The study was funded by Centers for Disease Control and Prevention and the Food and Drug Administration. The study authors' and editorial commentary authors' affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests, if any, are available in the study and the commentary, which are embargoed until 12:05 a.m. ET on Thursday, March 2. For an embargoed copy of the study and the commentary, please contact Jeremy Andereck (312-558-1770, firstname.lastname@example.org).
Published continuously since 1904, The Journal of Infectious Diseases is the premier global journal for original research on infectious diseases. The editors welcome major articles and brief reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. The journal is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases. For more information, visit http://www.